Functional Neuro-Oncology—Volume II

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 670

Special Issue Editor


E-Mail Website
Guest Editor
Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA
Interests: glioma; brain metastases; brain mapping; pituitary adenoma; endoscopic surgery; radiosurgery; fluorescent-guided surgery; clinical trials; biomarkers; proteomics; cerebrospinal fluid
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There is increasing evidence to support the notion that the nervous system plays a pivotal role in the progression of brain neoplasms, both primary and metastatic. Specifically, we know that the progression of glial tumors is driven by neuronal activity, mediated through secreted growth factors along with direct synaptic communication. Similarly, the influence of tumor cells on the modulation of the structural and electrical activity of brain circuits has also been demonstrated. This line of evidence has bearings on our understanding of the underpinnings of tumor progression and response to treatment, as well as brain plasticity and the therapeutic implications. Together, this has culminated in the rise in functional neuro-oncology as a specialist subset of neuro-oncology. The adoption of a functional approach to the management of brain tumors has improved our ability to achieve maximally safe tumor resection, elucidated several functional brain networks affected by tumors, and offered insight into the mechanism of brain tumor progression. However, this knowledge has also given rise to additional questions, concerning the role of the nervous system in the initiation of intrinsic brain tumors, the contribution of this interaction to the development of tumor-related epilepsy and strategies to mitigate it, the effect of various therapies on this interaction, and identifying opportunities for more effective therapeutic intervention. A more comprehensive understanding of this interplay can also be leveraged to improve cognitive rehabilitation. This Special Issue will highlight the latest developments in the field of functional neuro-oncology, with a particular focus on further elaborating on our mechanistic understanding and therapeutic opportunities.

Dr. Alireza Mansouri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain mapping
  • functional imaging
  • tractography
  • awake mapping
  • neuro-oncology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 266 KiB  
Review
Clinical Theranostics in Recurrent Gliomas: A Review
by Austin R. Hoggarth, Sankar Muthukumar, Steven M. Thomas, James Crowley, Jackson Kiser and Mark R. Witcher
Cancers 2024, 16(9), 1715; https://doi.org/10.3390/cancers16091715 - 28 Apr 2024
Viewed by 398
Abstract
Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of [...] Read more.
Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery. Full article
(This article belongs to the Special Issue Functional Neuro-Oncology—Volume II)
Back to TopTop